Old Web
English
Sign In
Acemap
>
Paper
>
P76.59 Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
P76.59 Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
2021
Baohui Han
Bo Zhang
Chunlei Shi
Zhiqiang Gao
Hua Zhong
Liwen Xiong
A. Gu
W. Wang
T. Chu
W. Zhang
H. Wang
Xu-Chao Zhang
Runbo Zhong
Keywords:
Oncology
egfr mutation
Internal medicine
Dacomitinib
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]